Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males With a Comparator Arm
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Setipiprant (Primary)
- Indications Alopecia
- Focus Proof of concept; Therapeutic Use
- Sponsors Allergan
- 18 Jul 2017 Planned number of patients changed from 152 to 163.
- 18 Jul 2017 Planned End Date changed from 31 Mar 2018 to 30 Aug 2018.
- 18 Jul 2017 Planned primary completion date changed from 31 Jan 2018 to 30 Jun 2018.